High grade prostatic adenocarcinoma with a partly intraductal growth pattern producing a mimic of urothelial carcinoma in situ

Introduction: Our previous studies showed elevated levels of Semaphorin3a (Sema3A) in the urine of patients with urothelial cancer compared to healthy patients. The aim of this study was to analyze the extent of Sema3A expression in normal and malignant urothelial tissue using immune-staining microscopic and morphometric analysis. Materials and Methods: Fifty-seven paraffin-embedded bladder samples were retrieved from our pathology archive and analyzed: 14 samples of normal urothelium, 21 samples containing low-grade urothelial carcinoma, 13 samples of patients with high-grade urothelial carcinoma, 7 samples containing muscle invasive urothelial carcinoma, and 2 samples with pure urothelial carcinoma in situ. All samples were immunostained with anti Sema3A antibodies. The area of tissue stained with Sema3A and its intensity were analyzed using computerized morphometry and compared between the samples’ groups. Results: In normal bladder tissue, very light Sema3A staining was demonstrated on the mucosal basal layer and completely disappeared on the apical layer. In low-grade tumor samples, cells in the basal layer of the mucosa were also lightly stained with Sema3A, but Seama3A expression intensified upon moving apically, reaching its highest level on apical cells exfoliating to the urine. In high grade urothelial tumors, Seama3A staining was intense in the entire thickness of the mucosa. In samples containing carcinoma in situ, staining intensity was high and homogenous in all the neoplastic cells. Conclusions: Sema3A may be serve as a potential non-invasive marker of urothelial cancer.

Download Full-text

High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder

Urology ◽

10.1016/j.urology.2005.06.135 ◽

2005 ◽

Vol 66 (6) ◽

pp. 90-107 ◽

Cited By ~ 121

Author(s):

Richard J. Sylvester ◽

Adrian van der Meijden ◽

J.A. Witjes ◽

Gerhard Jakse ◽

Norio Nonomura ◽

...

Keyword(s):

Urothelial Carcinoma ◽

Carcinoma In Situ ◽

High Grade

Download Full-text

Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder

Journal of Clinical Pathology ◽

10.1136/jclinpath-2017-204562 ◽

2017 ◽

Vol 71 (2) ◽

pp. 154-160 ◽

Cited By ~ 7

Author(s):

Anjelica Hodgson ◽

Bin Xu ◽

Raj Satkunasivam ◽

Michelle R Downes

Keyword(s):

Urothelial Carcinoma ◽

Carcinoma In Situ ◽

High Grade ◽

Disease Specific Survival ◽

Invasive Front ◽

Urothelial Carcinomas ◽

Carcinoma Of The Bladder ◽

The Impact ◽

Disease Specific

AimsInflammation and necrosis have been associated with prognosis in multiple epithelial malignancies. Our objective was to evaluate inflammation and necrosis in a cohort of patients with high-grade urothelial carcinomas of the bladder to determine their association with pathological parameters and their prognostic effect on relapse-free and disease-specific survival.MethodsA retrospective cohort that underwent radical cystectomy for urothelial carcinomas (n=235) was evaluated for invasive front and central inflammation using the Klintrup-Makinen assessment method. Necrosis was scored using a four-point scale. The relationship of inflammation and necrosis with stage, nodal status, carcinoma in situ, tumour size, margin status and vascular space invasion and the impact on relapse-free and disease-specific survival were calculated using appropriate statistical tests.ResultsOn multivariate analysis, invasive front inflammation (p=0.003) and necrosis (p=0.000) were independent predictors of relapse-free survival. Both invasive front inflammation (p=0.009) and necrosis (p=0.002) again were independent predictors of disease-specific survival. For pathological features, low invasive front inflammation was associated with lymphovascular space invasion (p=0.008), a positive soft tissue margin (p=0.028) and carcinoma in situ (p=0.042). Necrosis was statistically associated with tumours >3â€‰cm in size (p=0.013) and carcinoma in situ (p<0.001).ConclusionsNecrosis and invasive front inflammation are additional histological variables with independent prognostic relevance in high-grade urothelial carcinoma of the bladder.

Download Full-text

Anal condylomas: predictors of recurrence and progression to high-grade dysplasia / carcinoma in situ

10.26226/morressier.57c5383ed462b80296c9b6f6 ◽

2016 ◽

Author(s):

Armando Peixoto

Keyword(s):

Carcinoma In Situ ◽

High Grade Dysplasia ◽

High Grade ◽

Predictors Of Recurrence

Download Full-text

Urine cytology findings in patients with biopsy‐confirmed urothelial carcinoma in situ with plasmacytoid features

Cancer Cytopathology ◽

10.1002/cncy.22445 ◽

2021 ◽

Author(s):

Meredith M. Nichols ◽

Jordan P. Reynolds ◽

Jesse K. McKenney ◽

Marlo M. Nicolas ◽

Patrick J. McIntire ◽

...

Keyword(s):

Urothelial Carcinoma ◽

Carcinoma In Situ ◽

Urine Cytology

Download Full-text

Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06129-3 ◽

2021 ◽

Vol 186 (3) ◽

pp. 617-624

Author(s):

Kate R. Pawloski ◽

Audree B. Tadros ◽

Varadan Sevilimedu ◽

Ashley Newman ◽

Lori Gentile ◽

...

Keyword(s):

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Ductal Carcinoma ◽

Advanced Disease ◽

Breast Conserving Surgery ◽

Risk Profile ◽

High Grade ◽

Group A ◽

First Recurrence

Abstract Purpose Local recurrence after treatment of ductal carcinoma in situ (DCIS) with breast-conserving surgery (BCS) is more common than after mastectomy, but it is unclear if patterns of invasive recurrence vary by initial surgical therapy. Among patients with invasive recurrence after treatment for DCIS, we compared patterns of first recurrence between those originally treated with BCS vs. mastectomy. Methods From 2000 to 2016, women with an invasive recurrence occurring ≥ 6 months after initial treatment for DCIS were retrospectively identified. Clinicopathologic features and adjuvant treatment of the initial DCIS, as well as characteristics of first invasive recurrences, were compared between patients who had undergone BCS vs. mastectomy. Results 452 patients with an invasive recurrence after surgery for DCIS were identified: 367 patients (81%) had initially undergone BCS and 85 patients (19%) mastectomy. Patients originally treated with mastectomy were younger and were more likely to have had high grade, necrosis, and multifocal or multicentric DCIS (p < 0.001) compared with the BCS group. A higher proportion of invasive recurrences were local after BCS (93%; 343/367), whereas 88% (75/85) of recurrences after mastectomy were regional or distant (p < 0.001). The median time to first invasive recurrence was not different between surgical groups (BCS: 6.4 years vs. mastectomy: 5.5 years; p = 0.12). Conclusions Among women who experienced a first invasive recurrence after treatment for DCIS, those who had originally undergone mastectomy more commonly presented with advanced disease compared to those treated with BCS, likely related to the absence of the breast and the higher risk profile of their initial DCIS.

Download Full-text